Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront

Aligos Therapeutics, Inc.

2026-Q1 EPS reported -$2.21 revenue$2,830,000

Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.
Phase 2 B-SUPREME interim analysis: DSMB recommended increasing HBeAg- sample size to 100; futility criteria not met.
Exclusive license with Amoytop for Greater China: $25M upfront, up to $420M milestones plus tiered royalties.
Cash, equivalents, investments $54.9M at March 31, 2026 (Dec 31, 2025: $77.8M); expected to fund into Q4 2026 inclusive of $25M upfront.
Net loss Q1 2026: $23.0M ($2.21/share) vs net income $43.1M ($5.12/share) in Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported first quarter 2026 results: net income Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $, EPS $(2.21).

Period: first quarter 2026
Net income: Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $
EPS: $(2.21)
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $(2.21)

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.